

<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements" xlink:href="abus-20161231.xsd#CollaborationsContractsAndLicensingAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:href="abus-20161231.xsd#CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20161231.xsd#CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20161231.xsd#CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables" xlink:href="abus-20161231.xsd#CollaborationsContractsAndLicensingAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk" xlink:href="abus-20161231.xsd#ConcentrationsOfBusinessRisk" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskDetails" xlink:href="abus-20161231.xsd#ConcentrationsOfBusinessRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:href="abus-20161231.xsd#ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:href="abus-20161231.xsd#ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables" xlink:href="abus-20161231.xsd#ConcentrationsOfBusinessRiskTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:href="abus-20161231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="abus-20161231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="abus-20161231.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="abus-20161231.xsd#ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="abus-20161231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="abus-20161231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitments" xlink:href="abus-20161231.xsd#ContingenciesAndCommitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsDetails" xlink:href="abus-20161231.xsd#ContingenciesAndCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:href="abus-20161231.xsd#ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables" xlink:href="abus-20161231.xsd#ContingenciesAndCommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/DocumentAndEntityInformation" xlink:href="abus-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:href="abus-20161231.xsd#GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:href="abus-20161231.xsd#GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ImpairmentEvaluationsForIntangibleAssetsAndGoodwill" xlink:href="abus-20161231.xsd#ImpairmentEvaluationsForIntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ImpairmentEvaluationsForIntangibleAssetsAndGoodwillNarrativeDetails" xlink:href="abus-20161231.xsd#ImpairmentEvaluationsForIntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ImpairmentEvaluationsForIntangibleAssetsAndGoodwillSummaryOfCarryingValueOfIntangibleAssetsDetails" xlink:href="abus-20161231.xsd#ImpairmentEvaluationsForIntangibleAssetsAndGoodwillSummaryOfCarryingValueOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ImpairmentEvaluationsForIntangibleAssetsAndGoodwillTables" xlink:href="abus-20161231.xsd#ImpairmentEvaluationsForIntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxes" xlink:href="abus-20161231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="abus-20161231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesDetails" xlink:href="abus-20161231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesIncomeTaxReconciliationDetails" xlink:href="abus-20161231.xsd#IncomeTaxesIncomeTaxReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesTables" xlink:href="abus-20161231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited" xlink:href="abus-20161231.xsd#InterimFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedDetails" xlink:href="abus-20161231.xsd#InterimFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables" xlink:href="abus-20161231.xsd#InterimFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/LoanPayable" xlink:href="abus-20161231.xsd#LoanPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/LoanPayableDetails" xlink:href="abus-20161231.xsd#LoanPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations" xlink:href="abus-20161231.xsd#NatureOfBusinessAndFutureOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipment" xlink:href="abus-20161231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentDetails" xlink:href="abus-20161231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:href="abus-20161231.xsd#PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentTables" xlink:href="abus-20161231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapital" xlink:href="abus-20161231.xsd#ShareCapital" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:href="abus-20161231.xsd#ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalNarrativeDetails" xlink:href="abus-20161231.xsd#ShareCapitalNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedLiabilityStockOptionActivityDetails" xlink:href="abus-20161231.xsd#ShareCapitalNonVestedLiabilityStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityEquityOptionsDetails" xlink:href="abus-20161231.xsd#ShareCapitalNonVestedStockOptionActivityEquityOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:href="abus-20161231.xsd#ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:href="abus-20161231.xsd#ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:href="abus-20161231.xsd#ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalStockOptionActivityForLiabilityClassifiedOptionsDetails" xlink:href="abus-20161231.xsd#ShareCapitalStockOptionActivityForLiabilityClassifiedOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalStockOptionsOutstandingEquityOptionsDetails" xlink:href="abus-20161231.xsd#ShareCapitalStockOptionsOutstandingEquityOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfInformationEquityOptionsDetails" xlink:href="abus-20161231.xsd#ShareCapitalSummaryOfInformationEquityOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfInformationLiabilityClassifiedOptionsDetails" xlink:href="abus-20161231.xsd#ShareCapitalSummaryOfInformationLiabilityClassifiedOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfWarrantActivityDetails" xlink:href="abus-20161231.xsd#ShareCapitalSummaryOfWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalTables" xlink:href="abus-20161231.xsd#ShareCapitalTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalValuationAssumptionsAssumptionsWarrantsDetails" xlink:href="abus-20161231.xsd#ShareCapitalValuationAssumptionsAssumptionsWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalValuationAssumptionsEquityOptionsDetails" xlink:href="abus-20161231.xsd#ShareCapitalValuationAssumptionsEquityOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalValuationAssumptionsLiabilityClassifiedOptionsDetails" xlink:href="abus-20161231.xsd#ShareCapitalValuationAssumptionsLiabilityClassifiedOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPolicies" xlink:href="abus-20161231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="abus-20161231.xsd#SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:href="abus-20161231.xsd#SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:href="abus-20161231.xsd#SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfLiabilityClassifiedStockOptionsDetails" xlink:href="abus-20161231.xsd#SignificantAccountingPoliciesChangesInFairValueOfLiabilityClassifiedStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:href="abus-20161231.xsd#SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="abus-20161231.xsd#SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="abus-20161231.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesPolicies" xlink:href="abus-20161231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesTables" xlink:href="abus-20161231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SubsequentEvents" xlink:href="abus-20161231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="abus-20161231.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformation" xlink:href="abus-20161231.xsd#SupplementaryInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformationDetails" xlink:href="abus-20161231.xsd#SupplementaryInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformationTables" xlink:href="abus-20161231.xsd#SupplementaryInformationTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_0a0106fd-a196-7916-5adf-10dea44e4d50" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_1a5a9fc6-9840-2236-a82b-b1165c317cdb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredRevenue_0a0106fd-a196-7916-5adf-10dea44e4d50" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_1a5a9fc6-9840-2236-a82b-b1165c317cdb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredRevenue_0a0106fd-a196-7916-5adf-10dea44e4d50" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:type="extended">
    <link:loc xlink:href="abus-20161231.xsd#abus_ExposuretoCanadianDollar" xlink:label="loc_abus_ExposuretoCanadianDollar_D80F23337536FF7D493C878CC05F34D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_452ad43d-fa65-f205-7faa-792a5cefb9ba" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_ExposuretoCanadianDollar_D80F23337536FF7D493C878CC05F34D6" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_452ad43d-fa65-f205-7faa-792a5cefb9ba" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_19c041b8-a4d2-d9b0-7ac6-2e6c2de81ade" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_ExposuretoCanadianDollar_D80F23337536FF7D493C878CC05F34D6" xlink:to="loc_us-gaap_AccountsReceivableNet_19c041b8-a4d2-d9b0-7ac6-2e6c2de81ade" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_c6b5cdde-c977-8697-4021-ef35291647d0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_ExposuretoCanadianDollar_D80F23337536FF7D493C878CC05F34D6" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_c6b5cdde-c977-8697-4021-ef35291647d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_6abb8328-6056-4e30-86f3-0e87ddda7a25" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_ExposuretoCanadianDollar_D80F23337536FF7D493C878CC05F34D6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_6abb8328-6056-4e30-86f3-0e87ddda7a25" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:type="extended">
    <link:loc xlink:href="abus-20161231.xsd#abus_NetLiquidity" xlink:label="loc_abus_NetLiquidity_9eea89ed-64ed-ed1f-e9b0-fe99127a91df" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_452ad43d-fa65-f205-7faa-792a5cefb9ba" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_NetLiquidity_9eea89ed-64ed-ed1f-e9b0-fe99127a91df" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_452ad43d-fa65-f205-7faa-792a5cefb9ba" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_6abb8328-6056-4e30-86f3-0e87ddda7a25" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_NetLiquidity_9eea89ed-64ed-ed1f-e9b0-fe99127a91df" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_6abb8328-6056-4e30-86f3-0e87ddda7a25" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87a74df5-6262-b3a0-1a5b-b344f689ad60" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87a74df5-6262-b3a0-1a5b-b344f689ad60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_fdc0ed61-91fa-946a-6107-cae34d7fdf9d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_fdc0ed61-91fa-946a-6107-cae34d7fdf9d" xlink:type="arc" />
    <link:loc xlink:href="abus-20161231.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstanding" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_4313821142775E75A82187F92B86B428" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_4313821142775E75A82187F92B86B428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_1a5a9fc6-9840-2236-a82b-b1165c317cdb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_1a5a9fc6-9840-2236-a82b-b1165c317cdb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c0cb10ca-c667-9287-e07d-f3879727072b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c0cb10ca-c667-9287-e07d-f3879727072b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3b38d8c3-335c-53c8-5510-f59766fb81d5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3b38d8c3-335c-53c8-5510-f59766fb81d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaap_LongTermLoansPayable_40dd4942-5348-0175-b137-79fc78256987" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LongTermLoansPayable_40dd4942-5348-0175-b137-79fc78256987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8c99d26c-e257-b8ba-86ee-4f792a9452ce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_95ebcb07-1c4a-1ded-365f-edc9cd2fa101" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_95ebcb07-1c4a-1ded-365f-edc9cd2fa101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_3c67d026-8a2e-6845-efcf-9ef1a83fd83f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_LongTermInvestments_3c67d026-8a2e-6845-efcf-9ef1a83fd83f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_cba84dc8-4958-54c2-1b6f-e02bffbabe75" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_ShortTermInvestments_cba84dc8-4958-54c2-1b6f-e02bffbabe75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_c6b5cdde-c977-8697-4021-ef35291647d0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_c6b5cdde-c977-8697-4021-ef35291647d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_e84b8cf7-5c16-4daf-da6e-6c656f6f2757" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_IncomeTaxesReceivable_e84b8cf7-5c16-4daf-da6e-6c656f6f2757" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_605ccc51-868d-b1f1-b92c-a16352717bd3" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_605ccc51-868d-b1f1-b92c-a16352717bd3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_b6c36e3f-ea84-a440-1267-34444a0f8e78" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_Depreciation_b6c36e3f-ea84-a440-1267-34444a0f8e78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4f25f358-0eb6-8948-fd67-cb4acfcd66ec" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4f25f358-0eb6-8948-fd67-cb4acfcd66ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_fa260602-6369-9a36-3ad2-d6d2d1064552" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_fa260602-6369-9a36-3ad2-d6d2d1064552" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_81031a3c-c5d6-addf-8364-f979f72109de" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_81031a3c-c5d6-addf-8364-f979f72109de" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a630cdc5-a27f-054d-4089-cf5e52fc4cdd" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a630cdc5-a27f-054d-4089-cf5e52fc4cdd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3d247442-bbc8-32de-5a89-92957e1e5e6b" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3d247442-bbc8-32de-5a89-92957e1e5e6b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_74b08469-6f96-2804-5ecc-9a22aa904b19" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_74b08469-6f96-2804-5ecc-9a22aa904b19" xlink:type="arc" />
    <link:loc xlink:href="abus-20161231.xsd#abus_IncreaseDecreaseOtherDeferredCostsNet" xlink:label="loc_abus_IncreaseDecreaseOtherDeferredCostsNet_27873d10-4f8e-6499-472c-fe9912531493" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_abus_IncreaseDecreaseOtherDeferredCostsNet_27873d10-4f8e-6499-472c-fe9912531493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_e2449701-7d48-93f6-39a1-c54a5986b1da" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_e2449701-7d48-93f6-39a1-c54a5986b1da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_880f9863-dd81-7240-4418-c9f1ba4fd53e" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_880f9863-dd81-7240-4418-c9f1ba4fd53e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_38bb77ff-9a71-da5a-ae9a-8c89f84c6b01" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_38bb77ff-9a71-da5a-ae9a-8c89f84c6b01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4d29d890-f094-e626-55d5-ed3068d0c4ff" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4d29d890-f094-e626-55d5-ed3068d0c4ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_6cf2f23a-a032-a8d8-c4ee-06b3427d3949" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_6cf2f23a-a032-a8d8-c4ee-06b3427d3949" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_11be17d8-cdf3-5dff-9c97-3bc59877acaf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_11be17d8-cdf3-5dff-9c97-3bc59877acaf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_da5d3613-0426-0efc-e877-f02868c1f6ef" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_da5d3613-0426-0efc-e877-f02868c1f6ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_deec9633-9b66-f72b-a9df-3d2e95e18907" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_deec9633-9b66-f72b-a9df-3d2e95e18907" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_df373d95-9aed-55aa-3255-855344ae0add" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_df373d95-9aed-55aa-3255-855344ae0add" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_53bb4e1b-52b6-1bb1-1672-d14ea634a154" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_53bb4e1b-52b6-1bb1-1672-d14ea634a154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7125e76f-5cae-cb43-9a8d-1e5d11b5b5f7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7125e76f-5cae-cb43-9a8d-1e5d11b5b5f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_866e0d33-eabf-2b46-aabe-ae0e1d229b78" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_866e0d33-eabf-2b46-aabe-ae0e1d229b78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9f72449f-62f6-71b1-0128-c7088f4f3527" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9f72449f-62f6-71b1-0128-c7088f4f3527" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7263cb18-5b58-9955-8575-e8eaa5dac989" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7263cb18-5b58-9955-8575-e8eaa5dac989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_bf983ae9-4445-9fb2-ffa8-09746c4cbffd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_ContractsRevenue_bf983ae9-4445-9fb2-ffa8-09746c4cbffd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_b90f446c-aa6e-6f05-c6e4-a42529d65e7d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_LicensesRevenue_b90f446c-aa6e-6f05-c6e4-a42529d65e7d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61ca427c-a8f7-736f-ff6b-927d826fc7fa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2b63fac5-7a72-3880-3fd2-630099895af7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2b63fac5-7a72-3880-3fd2-630099895af7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_b6c36e3f-ea84-a440-1267-34444a0f8e78" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_Depreciation_b6c36e3f-ea84-a440-1267-34444a0f8e78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_278ba86a-a9bd-80a2-a5b0-b48318bde141" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_278ba86a-a9bd-80a2-a5b0-b48318bde141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3d247442-bbc8-32de-5a89-92957e1e5e6b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3d247442-bbc8-32de-5a89-92957e1e5e6b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4d29d890-f094-e626-55d5-ed3068d0c4ff" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4d29d890-f094-e626-55d5-ed3068d0c4ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ed735562-dfa2-f50c-cfbd-c90d6a562718" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ed735562-dfa2-f50c-cfbd-c90d6a562718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8bd26a17-2466-c9ca-826d-1c7167e5c7f9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8bd26a17-2466-c9ca-826d-1c7167e5c7f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_81031a3c-c5d6-addf-8364-f979f72109de" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_81031a3c-c5d6-addf-8364-f979f72109de" xlink:type="arc" />
    <link:loc xlink:href="abus-20161231.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_ba25bbfb-37b4-c2da-efd0-67bde89ef4f1" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_ba25bbfb-37b4-c2da-efd0-67bde89ef4f1" xlink:type="arc" />
    <link:loc xlink:href="abus-20161231.xsd#abus_OptionExercisedContractualOptionRevenueAmount" xlink:label="loc_abus_OptionExercisedContractualOptionRevenueAmount_f1e3e8fa-93a9-f9e4-0640-67bde8ad1e13" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_abus_OptionExercisedContractualOptionRevenueAmount_f1e3e8fa-93a9-f9e4-0640-67bde8ad1e13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00eaf688-6963-ad8a-03b8-e257d107b9c7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_00eaf688-6963-ad8a-03b8-e257d107b9c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5519a64c-2a56-b1d5-2ab3-ee16d7d2a7a5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5519a64c-2a56-b1d5-2ab3-ee16d7d2a7a5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2154b0cd-b6a4-a252-5801-385edf9d9702" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2154b0cd-b6a4-a252-5801-385edf9d9702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_c2ad5d03-49c6-819a-1ac6-e6584eea34ff" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_c2ad5d03-49c6-819a-1ac6-e6584eea34ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_b89e7a90-e5d1-031a-5e13-781005c7ec6e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_ab95e8f2-93e0-6140-6e56-a79823c16c0d" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_b89e7a90-e5d1-031a-5e13-781005c7ec6e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ImpairmentEvaluationsForIntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ImpairmentEvaluationsForIntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ImpairmentEvaluationsForIntangibleAssetsAndGoodwillSummaryOfCarryingValueOfIntangibleAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ImpairmentEvaluationsForIntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f549ecdb-d466-ac37-840e-8410ff9e5017" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f549ecdb-d466-ac37-840e-8410ff9e5017" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6826a434-0eba-a280-99df-92eaa6c3f055" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6826a434-0eba-a280-99df-92eaa6c3f055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_aaa13f1e-b61e-5e3a-0a94-85891bf5c2c2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_aaa13f1e-b61e-5e3a-0a94-85891bf5c2c2" xlink:type="arc" />
    <link:loc xlink:href="abus-20161231.xsd#abus_DeferredTaxAssetBookAmortizationInExcessOfTax" xlink:label="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_713d8654-44a6-ac4b-2c0a-fe9911774f38" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_713d8654-44a6-ac4b-2c0a-fe9911774f38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87cdbec2-773d-bc5a-3050-f979513ecb7f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87cdbec2-773d-bc5a-3050-f979513ecb7f" xlink:type="arc" />
    <link:loc xlink:href="abus-20161231.xsd#abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes" xlink:label="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7f222bba-4ff4-014a-6000-fe991205e3a7" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7f222bba-4ff4-014a-6000-fe991205e3a7" xlink:type="arc" />
    <link:loc xlink:href="abus-20161231.xsd#abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements" xlink:label="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_130fb9ea-caa6-4b70-4c90-fe99122003c3" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_130fb9ea-caa6-4b70-4c90-fe99122003c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_bfff09af-c352-005e-7d55-182952e9ad26" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_bfff09af-c352-005e-7d55-182952e9ad26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b782f46e-1b8c-4937-ee75-91eed84bcf8b" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b782f46e-1b8c-4937-ee75-91eed84bcf8b" xlink:type="arc" />
    <link:loc xlink:href="abus-20161231.xsd#abus_DeferredTaxAssetUpfrontLicenseFees" xlink:label="loc_abus_DeferredTaxAssetUpfrontLicenseFees_6406719c-4606-6579-14e0-fe9911625bd6" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_abus_DeferredTaxAssetUpfrontLicenseFees_6406719c-4606-6579-14e0-fe9911625bd6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_bdc6598b-bd97-4cc7-9f4f-5d5ac82ed0ed" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_344334d8-d156-37ea-1859-beb8bda06f5f" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_bdc6598b-bd97-4cc7-9f4f-5d5ac82ed0ed" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_36eb2c32-e98d-f713-df5d-5d9e7e50b88d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f549ecdb-d466-ac37-840e-8410ff9e5017" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_36eb2c32-e98d-f713-df5d-5d9e7e50b88d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f549ecdb-d466-ac37-840e-8410ff9e5017" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:type="arc" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6826a434-0eba-a280-99df-92eaa6c3f055" xlink:type="arc" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_aaa13f1e-b61e-5e3a-0a94-85891bf5c2c2" xlink:type="arc" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:to="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_713d8654-44a6-ac4b-2c0a-fe9911774f38" xlink:type="arc" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87cdbec2-773d-bc5a-3050-f979513ecb7f" xlink:type="arc" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:to="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7f222bba-4ff4-014a-6000-fe991205e3a7" xlink:type="arc" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:to="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_130fb9ea-caa6-4b70-4c90-fe99122003c3" xlink:type="arc" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_bfff09af-c352-005e-7d55-182952e9ad26" xlink:type="arc" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_b782f46e-1b8c-4937-ee75-91eed84bcf8b" xlink:type="arc" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:to="loc_abus_DeferredTaxAssetUpfrontLicenseFees_6406719c-4606-6579-14e0-fe9911625bd6" xlink:type="arc" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5e84d681-d720-597c-e306-ca1f497f20e3" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_bdc6598b-bd97-4cc7-9f4f-5d5ac82ed0ed" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b6c76c51-9163-a2c4-e48f-4450dcc2ac29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b6c76c51-9163-a2c4-e48f-4450dcc2ac29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_11289e28-2728-6877-19a4-d3db9fc50958" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_11289e28-2728-6877-19a4-d3db9fc50958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7988daaa-e3da-5096-4bce-cb601f0ef813" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7988daaa-e3da-5096-4bce-cb601f0ef813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_bad8f4f3-f415-9ec4-1169-fc6c9b538394" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_bad8f4f3-f415-9ec4-1169-fc6c9b538394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9535bc9d-9685-491b-9666-d4ee81b2fb72" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_9535bc9d-9685-491b-9666-d4ee81b2fb72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_194a4a4a-2356-cb9d-964a-dbbdb7f45ff5" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_194a4a4a-2356-cb9d-964a-dbbdb7f45ff5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/LoanPayable" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/LoanPayableDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapital" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalNonVestedLiabilityStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityEquityOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalStockOptionActivityForLiabilityClassifiedOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalStockOptionsOutstandingEquityOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfInformationEquityOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfInformationLiabilityClassifiedOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfWarrantActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalValuationAssumptionsAssumptionsWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalValuationAssumptionsEquityOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalValuationAssumptionsLiabilityClassifiedOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5987d7dd-ab82-bea6-ec65-c10216a0873a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5987d7dd-ab82-bea6-ec65-c10216a0873a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_fdc1f09c-fa08-4ac3-a9e1-6c69c28ccf56" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_fdc1f09c-fa08-4ac3-a9e1-6c69c28ccf56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue_b2c821e4-4bac-fd2f-be11-33aad257b973" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:to="loc_us-gaap_RestrictedInvestmentsAtFairValue_b2c821e4-4bac-fd2f-be11-33aad257b973" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_3c67d026-8a2e-6845-efcf-9ef1a83fd83f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:to="loc_us-gaap_LongTermInvestments_3c67d026-8a2e-6845-efcf-9ef1a83fd83f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_b641f7fc-d5fe-4341-ba13-4c84175dd42f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1cfdb95b-4854-99c5-9bcf-ed20746155ff" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_b641f7fc-d5fe-4341-ba13-4c84175dd42f" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1cfdb95b-4854-99c5-9bcf-ed20746155ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c0cb10ca-c667-9287-e07d-f3879727072b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_b641f7fc-d5fe-4341-ba13-4c84175dd42f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c0cb10ca-c667-9287-e07d-f3879727072b" xlink:type="arc" />
    <link:loc xlink:href="abus-20161231.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_30AFA460AEDCE71DC6ACA5487CB9503B" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_b641f7fc-d5fe-4341-ba13-4c84175dd42f" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_30AFA460AEDCE71DC6ACA5487CB9503B" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfLiabilityClassifiedStockOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87a74df5-6262-b3a0-1a5b-b344f689ad60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_6404190e-7530-9419-64f9-64b8c9675aae" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87a74df5-6262-b3a0-1a5b-b344f689ad60" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_6404190e-7530-9419-64f9-64b8c9675aae" xlink:type="arc" />
    <link:loc xlink:href="abus-20161231.xsd#abus_AccruedResearchandDevelopmentCurrent" xlink:label="loc_abus_AccruedResearchandDevelopmentCurrent_a497cdbf-89cf-4452-ff42-fe991167b691" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87a74df5-6262-b3a0-1a5b-b344f689ad60" xlink:to="loc_abus_AccruedResearchandDevelopmentCurrent_a497cdbf-89cf-4452-ff42-fe991167b691" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4ed680eb-fff6-d6ed-0239-7b9bb87e111b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87a74df5-6262-b3a0-1a5b-b344f689ad60" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4ed680eb-fff6-d6ed-0239-7b9bb87e111b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrent_28211ef7-5129-db02-d5ce-f4e8de32da7d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87a74df5-6262-b3a0-1a5b-b344f689ad60" xlink:to="loc_us-gaap_LeaseIncentivePayableCurrent_28211ef7-5129-db02-d5ce-f4e8de32da7d" xlink:type="arc" />
    <link:loc xlink:href="abus-20161231.xsd#abus_AccruedPayrollCurrent" xlink:label="loc_abus_AccruedPayrollCurrent_30fac7dc-740f-9e60-621d-67bde8c0be66" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87a74df5-6262-b3a0-1a5b-b344f689ad60" xlink:to="loc_abus_AccruedPayrollCurrent_30fac7dc-740f-9e60-621d-67bde8c0be66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_87a74df5-6262-b3a0-1a5b-b344f689ad60" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformationTables" xlink:type="extended" />
</link:linkbase>